文献速递细菌感染、耐药与抗菌药物

中东三国社区呼吸道感染病原菌耐药性调查(SOAR 2015-17)

Results from the Survey of Antibiotic Resistance (SOAR) 2015-17 in the Middle East (Kuwait, Lebanon and Saudi Arabia): data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints.
PubMed 文献 · J Antimicrob Chemother · 2020-01-01

该研究分析了2015-17年科威特、黎巴嫩和沙特阿拉伯社区获得性呼吸道感染分离的肺炎链球菌和流感嗜血杆菌,采用CLSI、EUCAST(剂量特异性)和PK/PD折点评估敏感性。结果显示三国肺炎链球菌对口服青霉素或低剂量静脉青霉素普遍不敏感,但高剂量折点下多数敏感;黎巴嫩分离株对多数抗生素高度敏感,科威特和沙特阿拉伯敏感性较低;沙特阿拉伯流感嗜血杆菌虽均为β-内酰胺酶阴性,但按CLSI和EUCAST分别有3.6%和12.7%对氨苄西林耐药。

要点

  • 科威特和沙特阿拉伯肺炎链球菌对青霉素不敏感率较高(39%-57.1%),但高剂量折点下多数仍敏感。
  • 黎巴嫩肺炎链球菌对多数抗生素敏感性>90%,科威特和沙特阿拉伯总体敏感性显著较低。
  • 沙特阿拉伯流感嗜血杆菌均产β-内酰胺酶阴性,但氨苄西林耐药率CLSI 3.6%、EUCAST 12.7%。

核心结论

  • 科威特和沙特阿拉伯肺炎链球菌抗生素敏感性相对较低,黎巴嫩敏感性普遍较高;沙特阿拉伯流感嗜血杆菌对多数抗生素敏感。

研究设计与样本

  • 2015-17年从科威特、黎巴嫩和沙特阿拉伯四家中心收集139株肺炎链球菌和55株流感嗜血杆菌(仅沙特阿拉伯),用CLSI肉汤微量稀释法测定MIC。

主要发现

  • 肺炎链球菌对青霉素不敏感率按CLSI口服或EUCAST低剂量静脉折点为39%(科威特)至57.1%(黎巴嫩),按CLSI静脉和EUCAST高剂量折点约90%(科威特和沙特阿拉伯)和100%(黎巴嫩)敏感。
  • 黎巴嫩肺炎链球菌对多数其他抗生素敏感性>90%,但头孢克洛、口服头孢呋辛和头孢泊肟(仅EUCAST折点)除外。
  • 沙特阿拉伯流感嗜血杆菌均β-内酰胺酶阴性,但氨苄西林耐药率CLSI为3.6%、EUCAST为12.7%,对其他抗生素敏感性高。

关键数值与推荐

  • 应用EUCAST低剂量和高剂量折点(阿莫西林、阿莫西林/克拉维酸、氨苄西林、青霉素、头孢曲松、克拉霉素、红霉素、左氧氟沙星和甲氧苄啶/磺胺甲噁唑)首次在SOAR研究中量化了提高剂量对敏感性的影响。

临床怎么用

  • 中东地区社区获得性呼吸道感染经验性治疗决策需考虑国家间耐药差异,高剂量青霉素折点下多数肺炎链球菌仍敏感。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVES: To determine antibiotic susceptibility of Streptococcus pneumoniae and Haemophilus influenzae isolates from community-acquired respiratory tract infections (CA-RTIs) collected in 2015-17 from Kuwait, Lebanon and Saudi Arabia. METHODS: MICs were determined by CLSI broth microdilution and susceptibility was assessed using CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. RESULTS: A total of 139 S. pneumoniae isolates were collected from four centres in Kuwait, Lebanon and Saudi Arabia in 2015-17 and 55 H. influenzae isolates were collected and analysed from Saudi Arabia over the same time period. Pneumococci from all three countries were commonly non-susceptible to penicillin based on CLSI oral or low-dose IV penicillin using EUCAST breakpoints (39% in Kuwait to 57.1% in Lebanon) but by CLSI IV and EUCAST high-dose breakpoints most isolates were susceptible (∼90% in Kuwait and Saudi Arabia, and 100% in Lebanon). Isolates from Lebanon were highly susceptible to most other antibiotics (>90%) except cefaclor, oral cefuroxime and cefpodoxime (EUCAST breakpoints only). Overall, susceptibility was significantly lower in Kuwait and Saudi Arabia than Lebanon. Although all H. influenzae isolates (Saudi Arabia only) were β-lactamase negative, 3.6% and 12.7% were ampicillin resistant by CLSI and EUCAST breakpoints, respectively. Otherwise susceptibility was high in H. influenzae. The application of different EUCAST breakpoints for low and higher doses for some of the antibiotics (amoxicillin, amoxicillin/clavulanic acid, ampicillin, penicillin, ceftriaxone, clarithromycin, erythromycin, levofloxacin and trimethoprim/sulfamethoxazole) allowed, for the first time in a SOAR study, the effect of raising the dosage on susceptibility to be quantified. CONCLUSIONS: Relatively low antibiotic susceptibility was observed in S. pneumoniae from Kuwait and Saudi Arabia in contrast to Lebanon, where rates of susceptibility were generally higher. Isolates of H. influenzae from Saudi Arabia were susceptible to most antibiotics. These factors are important in decision making for empirical therapy of CA-RTIs.

来源:J Antimicrob Chemother,查看原文。版权归原作者所有。

引用

  1. Torumkuney D, Mokaddas E, Jiman-Fatani A, et al. Results from the Survey of Antibiotic Resistance (SOAR) 2015-17 in the Middle East (Kuwait, Lebanon and Saudi Arabia): data based on CLSI, EUCAST (dose-specific) and pharmacokinetic/pharmacodynamic (PK/PD) breakpoints. J Antimicrob Chemother. 2020. PMID: 32337592. doi:10.1093/jac/dkaa084

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。